분석
2026년 9월 22일•1분 읽기
Celltrion's OmliClon Biosimilar Gains Strong Market Share in Europe
Celltrion's omalizumab biosimilar OmliClon expands to 26 European countries, achieving over 90% market share in Spain and exceeding sales targets in Italy.
분석
2026년 9월 7일•1분 읽기
Celltrion's Ramcima SC and US Zimpenra post 4.56 trillion KRW H1 sales
Ramcima SC and Zimpenra together generated 4.562 trillion KRW in the first half of the year, with strong growth in Europe and the US.
분석
2026년 9월 6일•1분 읽기
Celltrion expands Omliclo omalizumab biosimilar line with 300 mg launch in Europe
Celltrion has introduced the 300 mg dose of its omalizumab biosimilar Omliclo in Germany, the UK and France, extending its European portfolio for chronic urticaria and allergic asthma.
분석
2026년 9월 3일•1분 읽기
Celltrion Accelerates Biosimilar Growth in Europe and US, Launches CT-P68 Trial
Celltrion’s biosimilar business is building a virtuous growth cycle, expanding sales in Europe and the US while initiating a Phase 1 trial of CT-P68, a tremfya biosimilar.
분석
2026년 8월 31일•1분 읽기
Celltrion Biosimilars Gain Momentum in Europe, Omliclo Reaches 16% Share Q1
Celltrion's follow‑on biosimilars are expanding in Europe, with Omliclo achieving about 16% market share in Q1 2024, driven by a first‑mover strategy and direct sales network.
분석
2026년 8월 30일•1분 읽기
Celltrion’s bevacizumab biosimilar ‘베그젤마’ added to major US PBM formularies
Celltrion’s biosimilar 베그젤마 (bevacizumab) has been listed in Express Scripts and Optum formularies, strengthening its US oncology market foothold.
7
분석
2026년 8월 30일•1분 읽기
Celltrion Beats Q2 Market Expectations, Analysts Raise Target Prices
Celltrion reported Q2 revenue of 1.3 trillion KRW and operating profit of 430 billion KRW, surpassing consensus estimates, prompting analysts to lift target prices.